The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors

Author： Cao Fangyuan   Zwinderman Martijn R. H.   Dekker Frank J.  

Publisher： MDPI

E-ISSN： 1420-3049|23|3|551-551

ISSN： 1420-3049

Source： Molecules, Vol.23, Iss.3, 2018-03, pp. : 551-551

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Histone Deacetylase Inhibitors as Anticancer Drugs

By Eckschlager Tomas   Plch Johana   Stiborova Marie   Hrabeta Jan  

International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-07 ,pp. : 1414-1414

MDPI

Access to resources Recommend Favorite

Clinical Toxicities of Histone Deacetylase Inhibitors

By Subramanian Srividya   Bates Susan E.   Wright John J.   Espinoza-Delgado Igor   Piekarz Richard L.  

Pharmaceuticals, Vol. 3, Iss. 9, 2010-08 ,pp. : 2751-2767

MDPI

Access to resources Recommend Favorite

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

By Bishton Mark J.   Johnstone Ricky W.   Dickinson Michael   Harrison Simon   Prince H. Miles  

Pharmaceuticals, Vol. 3, Iss. 8, 2010-08 ,pp. : 2674-2688

MDPI

Access to resources Recommend Favorite

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics

By Chhabra Saurabh  

Pharmaceuticals, Vol. 10, Iss. 2, 2017-04 ,pp. : 40-40

MDPI

Access to resources Recommend Favorite

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies

By Ellis Leigh   Pili Roberto  

Pharmaceuticals, Vol. 3, Iss. 8, 2010-08 ,pp. : 2441-2469

MDPI

Access to resources Recommend Favorite